Development with Skymount is huge with their Deep Drug AI The joint development with Skymount is huge with their access to Deep Drug.AI
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
https://www.newsfilecorp.com/release/71207/iCo-Therapeutics-Announces-Joint-Development-of-iCo019-with-Skymount-Medical
https://www.lsu.edu/research/news/2020/0605-deepdrug.php
“DeepDrug has the power to perform 15 years of drug discovery and due diligence in 15 days and leads the pack in medical AI in terms of accuracy, speed, and performance.”—Zubin Kothawala, Skymount Medical
https://skymountmed.com/what-is-deepdrug/
https://skymountmed.com/pandemic-lab-programs/
Comapre the teams
https://skymountmed.com/team/
https://icotherapeutics.website/our-team/
Dr. Kishor Wasan and Dr. Peter Hnik - kind of a big deal.
Dr. Kishor M. Wasan
R.Ph., Ph.D., FAAPS, FCAHS, FCSPS
Fellow Canadian Academic of Health Sciences
Fellow, American Association of Pharmaceutical Sciences
Distinguished University Scholar & Adjunct Professor
Co-Director/Co-Founder, Neglected Global Diseases Initiative-UBC
Department of Urologic Sciences Faculty of Medicine The University of British Columbia
Chief Medical and Scientific Officer,
Skymount Medical US Inc.
Former Dean and Retired Professor, University of Saskatchewan
Dr. Peter Hnik, MD, MHSc
Chief Medical Officer and Director
Dr. Hnik received his medical degree from the Medical Faculty of Charles University of Prague in 1981. After practicing for years at the Eye Clinic of the Charles University Hospital where he performed surgery and consultation in glaucoma and neuro-ophthalmology, Dr. Hnik later joined the Eye Clinic of the University of British Columbia as part of the glaucoma research group. He received his Master of Health Sciences degree from the University of British Columbia in 1999. Prior to joining iCo Therapeutics, Dr. Hnik served as Associate Director of Clinical Research with QLT Inc., playing a critical role in designing and directing Visudyne clinical trials in AMD and diabetic retinopathy. He was also heavily involved in the publication, in-licensing and pharmacovigilance activities for Visudyne. He has authored numerous ocular publications and presentations at international forums. Dr. Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), the Drug Information Association (DIA), and the New York Academy of Sciences (NYA).